Mutated fibroblast growth factor (FGF) 1 and methods of use

US9925241B2 · kind B2 · utility

Assignee

• Salk Institute for Biological Studies · US

Inventors

• Jae Myoung Suh · San Diego, US
• Michael Downes · Village of La Jolla, US
• Ronald M. Evans · Village of La Jolla, US
• Annette Atkins · Village of La Jolla, US
• Ruth T. Yu · Village of La Jolla, US

Key dates

• Filing date: Oct 21, 2014
• Grant date: Mar 27, 2018
• Expiry date: Oct 21, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/501
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a β-Klotho-binding protein, an FGFR1c-binding protein, a β-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.